These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 23198869)

  • 1. Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly.
    Matsumoto T; Yokota K; Sawada M; Sakakibara A; Shibata S; Yasue S; Tomita Y; Yatsuya H; Akiyama M
    J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1514-20. PubMed ID: 23198869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
    Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
    J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy of malignant melanoma].
    Ishihara K
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):23-7. PubMed ID: 7529980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival.
    Kawada K; Kawano T; Nagai K; Nishikage T; Nakajima Y; Tokairin Y; Ogiya K; Tanaka K; Iwai T
    Gastrointest Endosc; 2007 Aug; 66(2):408-10. PubMed ID: 17643724
    [No Abstract]   [Full Text] [Related]  

  • 5. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study.
    Aoyagi S; Hata H; Homma E; Shimizu H
    Oncology; 2012; 82(3):139-46. PubMed ID: 22433252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis.
    Yanagi T; Hata H; Homma E; Kitamura S; Imafuku K; Shimizu H
    Clin Exp Dermatol; 2017 Oct; 42(7):781-785. PubMed ID: 28649738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New combination chemotherapy for malignant melanoma--PAV(peplomycin, ACNU, VCR) therapy].
    Ikeda S; Tajima K; Miyasato H; Terakado T; Suzuki T; Miura T
    Gan To Kagaku Ryoho; 1983 Oct; 10(10):2198-204. PubMed ID: 6194756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma.
    Nitta Y; Ikeya T; Sakakibara A; Tomita Y
    J Dermatol; 2011 Feb; 38(2):164-8. PubMed ID: 21269313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy of malignant melanoma].
    Ishihara K; Yamazaki N; Asano K
    Gan To Kagaku Ryoho; 1993 Aug; 20(10):1287-92. PubMed ID: 7688498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy (part II)].
    Ishihara K; Hayasaka K; Ikeda S; Terakado T; Kukita A; Seki Y; Jimbow K; Suzuki M
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):467-73. PubMed ID: 6703721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma.
    Nagatani T; Ichiyama S; Onuma R; Miyazawa M; Matsuzaki T; Miyagawa K; Baba N; Uchiyama M; Nakajima H
    Acta Derm Venereol; 1995 Nov; 75(6):494. PubMed ID: 8651034
    [No Abstract]   [Full Text] [Related]  

  • 13. [Case of metastatic malignant melanoma responded to combination chemotherapy with DTIC].
    Tamura T; Miyamoto H; Harada M; Makinoya T; Yamamoto M; Miyoshi Y; Komi N
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):327-32. PubMed ID: 6582806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
    Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy].
    Jimbow K; Takahashi H; Ishihara K; Hayasaka K; Kukita A; Seki Y; Ikeda S; Terakado T
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1942-9. PubMed ID: 7184382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
    Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
    Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Malignant melanoma].
    Matsumoto K; Saida T
    Nihon Rinsho; 2006 Jul; 64(7):1321-6. PubMed ID: 16838651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS; Neuberg D; Park Y; Kirkwood JM
    Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
    Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
    Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.